Capacity to consent (legally competent, written informed consent including data protection)
Diagnosis of depression (at least moderate severity, BDI-II ≥ 20), including major depressive episode in bipolar disorder
Comorbid diagnosis of Post-COVID-19 condition (WHO definition)
Insufficient improvement of depressive symptoms under psychopharmacological treatment
Stable psychopharmacological medication for at least 4 weeks prior to start of iTBS
You may not be if
Age \<18 years or \>65 years
Pregnancy, planned pregnancy, or breastfeeding
Legal guardianship or cognitive impairment preventing valid informed consent
Severe developmental disorder or intellectual disability
Acute or chronic substance abuse (alcohol, prescription drugs, or illicit drugs)
Current treatment with benzodiazepines or Z-substances
Acute suicidality
Psychotic symptoms
Severe neurological disorder (e.g., major brain injury, neurodegenerative disease)
Ongoing treatment with another neurostimulation method (ECT, TMS, VNS)
Contraindications to TMS, including: Intracranial metal, implants, shunts, Cochlear implant, pacemaker, implantable defibrillator, History of seizures or epileptiform EEG
Severe general medical illness (e.g., anemia requiring transfusion, severe arrhythmias, cardiomyopathy)
Clareo Health | IMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 Condition
